NCT05182866View on ClinicalTrials.gov

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

July 11, 2024

Study Completion Date

June 30, 2026

Conditions
Head and Neck CancerSquamous Cell Carcinoma of Head and Neck
Interventions
COMBINATION_PRODUCT

ASP-1929 Photoimmunotherapy

ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy

Trial Locations (1)

20892

Center for Cancer Research, Bethesda

All Listed Sponsors
collaborator

Shimadzu Corporation

UNKNOWN

collaborator

National Cancer Institute (NCI)

NIH

lead

Rakuten Medical, Inc.

INDUSTRY